Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCL-2 study of daratumumab with chemotherapy and stem cell transplantation in primary plasma cell leukemia
2024-515037-15-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, bortezomib, lenalidomide and dexamethasone in plasma cell leukaemia (PCL), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Very good partial response or better rate after induction. Planned start Nov 2024; status: authorised.
02
Drugs
daratumumabbortezomiblenalidomidedexamethasone
03
Conditions
plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on 2024-515037-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515037-15-00.